Acute upper respiratory infections Respiratory
Conditions
Interventions
Stage 1:
We will firstly work with up to 30 healthy participants to develop information to help patients do a home assessment and throat swab/saliva tests and know what to look for when they have a so
Sponsors
University of Southampton
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Sore throat 16 years <= 65 years 7. Parents of children aged 3 - 16 years
Exclusion criteria
Exclusion criteria: 1. Any significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data, for example recent surgery to the pharynx or acute illness which would contraindicate swabbing eg epiglottis 2. Current or recent (within 3 months) involvement in a clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility outcome measures: 1. Recruitment rate (recruited participants/month) throughout the study (measured using the Lifeguide database) 2. Data completion rates throughout the study (Lifeguide database) 3. Number of participants able to assess each clinical feature and able to obtain an adequate throat swabs + saliva samples (measured during video call and using FeverPAIN and Centor score) 4. Description of participants, including the proportions with a positive throat swab culture for group A, C and G streptococcus, and demographics (age gender, ethnicity, etc.) (Lifeguide database and laboratory results) 5. Number of participants willing to provide a second throat swab +/- saliva samples for inflammatory marker testing (measured during video call) 6. The distribution of inflammatory marker concentrations by presence/absence of pathogenic streptococci, and by adequacy of swabbing achieved (Laboratory results) 7. The impact of sample storage/transport time on inflammatory marker concentrations (Laboratory results) 8. Views of participating participants/parents on acceptability, barriers and facilitators to assessing clinical features and obtaining home (self-)tests assessed by interview (analysis by noting and recording initial themes and then conducting systematic and detailed open coding using NVivo) 9. Assessment of the quality of participant assessment of features (such as lymph node enlargement and tenderness) and swabbing/saliva tests assessed by interview (analysis by noting and recording initial themes and then conducting systematic and detailed open coding using NVivo) | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, United Kingdom
Outcome results
None listed